Overview

Subject Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris

Status:
Completed
Trial end date:
2019-12-23
Target enrollment:
Participant gender:
Summary
Subject Reported Outcomes with use of Trifarotene 50 μg/g Cream in Subjects with Moderate Facial and Truncal Acne Vulgaris
Phase:
Phase 3
Details
Lead Sponsor:
Galderma R&D
Treatments:
Trifarotene